Please login to the form below

Not currently logged in
Email:
Password:

Zinfandel

This page shows the latest Zinfandel news and features for those working in and with pharma, biotech and healthcare.

Another Alzheimer's bust as Merck & Co stops verubecestat study

Another Alzheimer's bust as Merck & Co stops verubecestat study

Since the start of the year, Boehringer Ingelheim has stopped development of its PDE9a inhibitor BI 4093906, Takeda and Zinfandel abandoned efforts to repurpose diabetes drug pioglitazone for the disease, and

Latest news

  • Takeda and Zinfandel abandon Alzheimer’s drug Takeda and Zinfandel abandon Alzheimer’s drug

    Takeda and Zinfandel abandon Alzheimer’ s drug. Pioglitazone failed to show therapeutic improvements in late-stage testing. ... A phase III trial of pioglitazone in Alzheimer’s disease has been terminated by Takeda and partner Zinfandel Therapeutics

  • Takeda continues Actos resurrection as Alzheimer's drug Takeda continues Actos resurrection as Alzheimer's drug

    Takeda and partner Zinfandel Pharma have started a phase III trial of pioglitazone in people at risk of developing the symptoms of Alzheimer's disease (AD). ... Earlier studies of pioglitazone in symptomatic AD patients showed only a small benefit from

  • Non-amyloid therapies emerging for Alzheimer's at AAIC Non-amyloid therapies emerging for Alzheimer's at AAIC

    Takeda and Zinfandel Pharmaceuticals highlighted a new approach to identifying individuals who are at risk of developing Alzheimer's dementia which could be used to support clinical trials of early treatments.

  • Archive listing

    Takeda and Zinfandel abandon Alzheimer’ s drug.

  • Creative partnerships

    Preclinical. 100. Zinfandel Pharma/Takeda. TOMM40 assay, biomarker for risk of developing Alzheimer's disease.

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...
World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...

Infographics